SecBot SecBot
DEFA14A ·Filed Mar 20, 2026

MRKR

Marker Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed8mo ago SEC0001104659-26-032708
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the shareholder vote outcome, particularly on the share increase proposal, as approval would significantly increase potential dilution. The request to adjourn the meeting suggests management may be uncertain about securing enough votes.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.31
T+0 close · Mar 20, 2026 · via day close
Latest settled
+3.05%
T+60 · $1.35
Vs SPY
−10.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $1.31entry
  2. T+1 · 8mo ago −3.82%α −3.46% · $1.26
  3. T+5 · 8mo ago −5.34%α −1.78% · $1.24
  4. T+20 · 7mo ago +19.08%α +11.66% · $1.56
  5. T+60 · 5mo ago +3.05%α −10.00% · $1.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Marker Therapeutics is holding its 2026 annual meeting where shareholders will vote on several proposals, including the election of directors, approval of executive compensation, and a critical proposal to increase authorized shares from 30 million to 130 million. The company is also seeking ratification of its auditors and approval to adjourn the meeting if needed to secure votes for the share increase.

Key Facts

  • Annual meeting scheduled for May 1, 2026.
  • Proposal 3 seeks to increase authorized common stock from 30 million to 130 million shares.
  • The company is asking for approval to adjourn the meeting (Proposal 6) if there are insufficient votes for the share increase.
  • Board recommends voting 'FOR' on all proposals.
  • The filing is a definitive proxy statement (DEFA14A) for a routine shareholder vote.

Financial Impact

The share increase would allow the company to issue up to 100 million additional shares.

dilution

Risk Factors

  • Shareholder approval of the share increase could lead to significant dilution of existing shareholders.
  • Failure to approve the share increase could limit the company's ability to raise capital or complete future transactions.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-032708
Document: 0001104659-26-032708-index-headers.html0001104659-26-032708
Document: 0001104659-26-032708-index.html0001104659-26-032708
Document: 0001104659-26-032708.txt0001104659-26-032708

Track record

5 reports on MRKR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Oct 19, 202628d ago 8-K Bullish 5/10 Entry $1.20 to $0.8700 Now $0.8300 −30.83% ▼ −27.50% −24.04% vs SPY
  2. Oct 19, 202628d ago Press Release Bullish 5/10 Entry $1.20 to $0.8286 Now $0.8300 −30.83% ▼ −30.95% −27.49% vs SPY
  3. Mar 20, 202634w ago DEFA14A Neutral 4/10 Viewing Entry $1.31 to $1.56 Now $0.8300 −36.64% ▲ +19.08% +11.66% vs SPY
  4. Mar 19, 202634w ago 8-K Mixed 6/10 Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
  5. Mar 18, 202634w ago Press Release Mixed 6/10 Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 20, 2026